David E. Griffith
Pulmonologist and Professor of Medicine at National Jewish Health, Denver, expert in nontuberculous mycobacterial (NTM)/MAC lung disease, tuberculosis, and bronchiectasis.
1
APPEARANCES
1
PODCASTS
Oct 21, 2026
Charles L. DaleyHOST
Okay, so let's switch to critical first steps, and for that, I'm going to welcome Dave.
David E. GriffithGUEST
So we're going to talk about integrating treatment plans for newly diagnosed lung disease.
David E. GriffithGUEST
So for instance, sputum positive AFB smear or a cavity are strong predictors of progressive MAC lung disease and are usually adequate or making a decision to begin treatment.
David E. GriffithGUEST
Now certainly, also someone who has extensive multilobar lung parenchymal involvement would fall in that category as well.
David E. GriffithGUEST
In terms of following patients without MAC medication, I would only say we do it a lot.
23 MINS LATER